Organon completes licensing agreement for MIUDELLA IUD
The hormone-free copper IUD expands Organon's contraception portfolio and is FDA-approved for up to three years.
See the latest news and media coverage for Organon. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare company focused on women's health
organon.comLast updated
In short: Organon agreed to be acquired by Sun Pharma for $11.75 billion, while also securing expanded FDA and EC approvals for key biosimilar treatments.
The hormone-free copper IUD expands Organon's contraception portfolio and is FDA-approved for up to three years.
The approval is for a dysmenorrhea product, enhancing access and recognition of menstrual pain as an undertreated women's health issue, and credits Organon Japan's collaborative efforts.
The FDA approved the biosimilar for treating CAR T-cell induced CRS and COVID-19 in patients aged 2 and older.
POHERDY is the first approved pertuzumab biosimilar in Europe for HER2-positive breast cancer treatments. It expands access via Organon's commercialization rights.
Organon Canada and Henlius launch denosumab biosimilars Bildyos and Tuzemty in Canada, expanding access for osteoporosis and cancer bone care.
Organon gains rights to Samsung biosimilar in Canada...
The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to...
The investigation concerns whether the Organon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction...
Track Organon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.